| Autor: |
Sumichika Y; Department of Rheumatology, Fukushima Medical University School of Medicine, Japan., Temmoku J; Department of Rheumatology, Fukushima Medical University School of Medicine, Japan., Saito K; Department of Rheumatology, Fukushima Medical University School of Medicine, Japan., Yoshida S; Department of Rheumatology, Fukushima Medical University School of Medicine, Japan., Matsumoto H; Department of Rheumatology, Fukushima Medical University School of Medicine, Japan., Watanabe G; Department of Nephrology and Hypertension, Fukushima Medical University School of Medicine, Japan., Utsumi A; Department of Diagnostic Pathology, Fukushima Medical University, School of Medicine, Japan., Fujita Y; Department of Rheumatology, Fukushima Medical University School of Medicine, Japan., Matsuoka N; Department of Rheumatology, Fukushima Medical University School of Medicine, Japan., Asano T; Department of Rheumatology, Fukushima Medical University School of Medicine, Japan., Sato S; Department of Rheumatology, Fukushima Medical University School of Medicine, Japan., Migita K; Department of Rheumatology, Fukushima Medical University School of Medicine, Japan. |
| Abstrakt: |
Coronavirus disease 2019 (COVID-19) is a respiratory viral disease, and several cases of autoimmune diseases have been reported after infection. This report presents the case of a 38-year-old Japanese woman who developed systemic lupus erythematosus (SLE) following COVID-19. Clinical manifestations included dermatological complications, joint pain, and positive autoantibodies. The patient met the SLE classification criteria, and renal involvement was observed. Her symptoms improved with immunosuppressive therapy. A literature review identified 10 similar cases, those with lymphopenia and renal involvement. SLE should be considered in patients with persistent nonspecific symptoms after COVID-19 infection, particularly when hematologic and renal involvement are present. |
